Mode
Text Size
Log in / Sign up
Phase 2 N=14 Randomized Quadruple-blind Treatment

Lexapro for the Treatment of Traumatic Brain Injury (TBI) Depression & Other Psychiatric Conditions

TBI · Major Depression · Other Psychiatric Disorders

Enrolled (actual)
14
Serious AEs
0.0%
Results posted
Oct 2016
Primary outcome: Primary: Montgomery-Asberg Depression Rating Scale (MADRS) at Baseline — 29.5; 33.6 units on a scale

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Escitalopram (Drug); Placebo (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Johns Hopkins University
Primary completion
Dec 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
Montgomery-Asberg Depression Rating Scale (MADRS) at Baseline
29.5; 33.6
PRIMARY
Montgomery-Asberg Depression Rating Scale (MADRS)
11.2; 7
SECONDARY
Clinical Global Impression (CGI) - Severity at Baseline
4.5; 4.8
SECONDARY
Clinical Global Impression (CGI)- Improvement
2.7; 2.1
SECONDARY
Clinical Anxiety Scale (CAS)
6.3; 3.9
SECONDARY
Clinical Anxiety Scale (CAS)
6.3; 3.9
SECONDARY
Satisfaction With Life (SWL)
21.2; 22.6
SECONDARY
Satisfaction With Life (SWL)
21.2; 22.6
SECONDARY
Quality of Life (QWL)
75.2; 78.7
SECONDARY
Quality of Life (QWL)
75.2; 78.7
SECONDARY
Disability Rating Scale (DRS)
0.7; 0.6
SECONDARY
Disability Rating Scale (DRS)
0.7; 0.6
SECONDARY
Mini Mental Status Exam (MMSE)
29.7; 29.0
SECONDARY
Mini Mental Status Exam (MMSE)
29.7; 29.0

Summary

This research is being done to see if a drug called escitalopram (Lexapro) is helpful to people who are suffering from depression after traumatic brain injury (TBI).

Eligibility Criteria

Inclusion Criteria

  • Closed head injury
  • Fulfill Diagnostic and Statistical Manual Diploma in Social Medicine (DSM) IV criteria "Major Depressive Disorder"
  • 18 years of age or older
  • Able to provide informed consent
  • Stable medical history

Exclusion Criteria

  • History of Stroke, Encephalitis, Seizures, or any other pre-TBI neurological diseases
  • History of mental retardation
  • Alcohol or Substance dependence in the last 1 year
  • Inability to undergo MRI scan
  • Pregnancy
  • Current use of any psychotropic medications including any antidepressants, antipsychotics, anxiolytics, or sedative hypnotics
  • Poor response to escitalopram in the past
  • Acutely suicidal or requiring inpatient psychiatric hospitalization, as determined by the study psychiatrist
  • Good medication response to another antidepressant in the past
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01368432). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search